| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5698171 | Clinical Oncology | 2014 | 9 Pages |
Abstract
The maximum tolerable dose has not yet been reached in any study arm. SRS-VMAT resulted in positive early clinical results in terms of tumour response, local control rate and acute toxicity.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
F. Deodato, S. Cilla, G. Macchia, G. Torre, L. Caravatta, G. Mariano, S. Mignogna, M. Ferro, G.C. Mattiucci, M. Balducci, V. Frascino, A. Piermattei, G. Ferrandina, V. Valentini, A.G. Morganti,